Figure 1. AOM Mirror Study Design

Prospective

• From the AOM Mirror study analysis, which investigated psychiatric hospitalization rates among patients switching from oral antipsychotic standard of care (SOC) to AOM in a multicenter, open-label mirror study of patients with schizophrenia who are aged 18–65 years (AOM Mirror study; NCT01432444).

• Total psychiatric hospitalization rates were reduced from 41.5% in the SOC, 6-month retrospective period to 14.2% in the AOM 6-month prospective period (P < .0001).

• Among all patients who relapsed during the retrospective SOC treatment period (n=76), 22.4% had a relapse during the prospective AOM treatment period (n=17, P<.0001).

Table 1. Model Inputs

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Retrospective</th>
<th>Prospective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalizations per patient hospitalized while on AOM</td>
<td>1.16</td>
<td>0.16</td>
</tr>
<tr>
<td>Average estimated number of hospitalizations per patient during the prospective period</td>
<td>1.16</td>
<td>0.16</td>
</tr>
<tr>
<td>Average length of stay (days)</td>
<td>12.36</td>
<td>8.36</td>
</tr>
<tr>
<td>Drug cost (AOM per month)</td>
<td>$1,436</td>
<td>$1,146</td>
</tr>
<tr>
<td>Cost of concurrent oral antipsychotic at the time of AOM initiation</td>
<td>$275</td>
<td>$295</td>
</tr>
<tr>
<td>Total cost (AOM per month)</td>
<td>$2,111</td>
<td>$2,375</td>
</tr>
<tr>
<td>Hospitalization charges for AOM treatment</td>
<td>$300,000</td>
<td>$250,000</td>
</tr>
</tbody>
</table>

Figure 2. Model Structure

Retrospective oral SOC treatment period

Prospective AOM treatment period

Figure 3. Hospitals and Hospital Days per Patient Before and After Switching From SOC to AOM

Change in Costs

Six-month costs before and after the switch to AOM are summarized in Figure 4.

• Total costs for patients with at least 1 hospitalization in the retrospective period decreased by 36% from $16,415 in the retrospective period to $23,313 in the prospective period.

Figure 4. Estimated 6-Month Costs per Patient Before and After Switching From SOC to AOM

Acknowledgments

This study was funded by Otsuka America Pharmaceutical, Inc., and In Lurud AS. Medical writing assistance with partial funding was provided by Scientific Connections, Inc.

Declaration of Financial/Other Relationship

Siddhesh A. Kamat, Christopher M. Blanchette, Michele Wilson, Stephanie Earnshaw, Steve Offord, Benjamin Gutierrez, Anna Eramo, and Ross A. Baker are employees of Otsuka America Pharmaceutical, Inc. No other disclosures.

Conclusions

• Among patients with schizophrenia having at least 1 previous psychiatric hospitalization, treatment initiation with AOM may present cost-saving opportunities for health plans as well as improve patient outcomes by reducing the rate of psychiatric hospitalizations.

References